Anti-mouse PD-L1 (B7-H1)-InVivo

Catalog No.A2115       

       Clone No.10F.9G2

Print

Anti-mouse PD-L1 (B7-H1)-InVivo (Clone:10F.9G2) monoclonal antibody reacts with mouse PD-L1 (also known as B7-H1, CD274). The 10F.9G2 antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80).

Technical Data

Formulation PBS Buffer, PH 7.4
Molecular Weight 150 kDa
Clone 10F.9G2
Immunogen Mouse CD274
Isotype Rat,IgG2b, κ
Application in vivo PD-L1 blockade,IHC (frozen),FCM
Source CHO
Storage
(From the date of receipt)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purification protein G
Sterility 0.2 μM filtered

Customer Product Validation

Data from [Data independently produced by , ]

Selleck's Anti-mouse PD-L1 (B7-H1)-InVivo has been cited by 12 publications

NRIR promotes immune escape in hepatocellular cancer by regulating IFNγ-induced PD-L1 expression [ J Adv Res, 2025, S2090-1232(25)00133-X] PubMed: 40023249
ENTPD8 overexpression enhances anti-PD-L1 therapy in hepatocellular carcinoma via miR-214-5p inhibition [ iScience, 2025, 28(2):111819] PubMed: 39995876
Interleukin-17A facilitates tumor progression via upregulating programmed death ligand-1 expression in hepatocellular carcinoma [ World J Gastrointest Oncol, 2025, 17(1):97831] PubMed: 39817127
Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape [ Cancer Commun (Lond), 2024, 10.1002/cac2.12545] PubMed: 38734931
Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape [ Cancer Commun (Lond), 2024, 44(6):670-694] PubMed: 38734931
Bioactive nanocomposite hydrogel enhances postoperative immunotherapy and bone reconstruction for osteosarcoma treatment [ Biomaterials, 2024, 312:122714] PubMed: 39079462
TNKS1BP1 facilitates ubiquitination of CNOT4 by TRIM21 to promote hepatocellular carcinoma progression and immune evasion [ Cell Death Dis, 2024, 15(7):511.] PubMed: 39019859
TNKS1BP1 facilitates ubiquitination of CNOT4 by TRIM21 to promote hepatocellular carcinoma progression and immune evasion [ Cell Death Dis, 2024, 15(7):511] PubMed: 39019859
[ Int J Nanomedicine, 2024, ] PubMed: 38348177
Precision USPIO-PEG-SLex Nanotheranostic Agent Targeted Photothermal Therapy for Enhanced Anti-PD-L1 Immunotherapy to Treat Immunotherapy Resistance [ Int J Nanomedicine, 2024, 19:1249-1272] PubMed: 38348177

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.